1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Arteriosclerosis - Pipeline Review, H2 2014

Arteriosclerosis - Pipeline Review, H2 2014

  • July 2014
  • -
  • Global Markets Direct
  • -
  • 59 pages

Arteriosclerosis - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Arteriosclerosis - Pipeline Review, H2 2014’, provides an overview of the Arteriosclerosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Arteriosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arteriosclerosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Arteriosclerosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Arteriosclerosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Arteriosclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Arteriosclerosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Arteriosclerosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Arteriosclerosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Arteriosclerosis - Pipeline Review, H2 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Arteriosclerosis Overview 7
Therapeutics Development 8
Pipeline Products for Arteriosclerosis - Overview 8
Pipeline Products for Arteriosclerosis - Comparative Analysis 9
Arteriosclerosis - Therapeutics under Development by Companies 10
Arteriosclerosis - Therapeutics under Investigation by Universities/Institutes 11
Arteriosclerosis - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Arteriosclerosis - Products under Development by Companies 15
Arteriosclerosis - Products under Investigation by Universities/Institutes 16
Arteriosclerosis - Companies Involved in Therapeutics Development 17
Johnson and Johnson 17
Kowa Company, Ltd. 18
Nippon Shinyaku Co., Ltd. 19
KunWha Pharmaceutical Co., Ltd. 20
AnGes MG, Inc. 21
LTT Bio-Pharma Co., Ltd. 22
CytoTools AG 23
Arteriosclerosis - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
beperminogene perplasmid - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
ecraprost - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
K-134 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
selexipag - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
sarpogrelate SR - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
LMW-0x - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
Gene Therapy for Arteriosclerosis and Endothelial Dysfunction - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
LT-0101 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
VE-Statin - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Arteriosclerosis - Recent Pipeline Updates 46
Arteriosclerosis - Dormant Projects 50
Arteriosclerosis - Discontinued Products 51
Arteriosclerosis - Product Development Milestones 52
Featured News and Press Releases 52
May 01, 2014: The Medicines Company and Alnylam Announce Presentation of New Pre-Clinical Data on PCSK9 at Arteriosclerosis, Thrombosis and Vascular Biology 2014 Scientific Sessions 52
Nov 15, 2012: AtheroNova Receives Notice Of Issuance Of U.S. Patent 8,304,383 52
Nov 02, 2012: AlphaCore Receives Orphan Drug Designation For ACP-501 From European Medicines Agency 53
Aug 26, 2012: Merck Provides Update On Tredaptive Development Program 53
Jul 09, 2012: AtheroNova Receives Notice Of Allowance For US Patent Application 12/024,908 53
Apr 25, 2012: Frontage Signs Agreement For Development Of Clinical Trial Supplies 54
Nov 02, 2011: Resverlogix Commences Dosing In ASSURE Phase IIb IVUS Clinical Trial Targeting High-Risk Cardiovascular Disease Patients 55
Mar 21, 2011: FDA Accepts Arisaph's Investigational New Drug Application For Dyslipidemia Drug 55
Jan 04, 2011: AnGes MG Announces Publication Of Collategene Clinical Research Data In Arteriosclerosis, Thrombosis And Vascular Biology 56
Jul 26, 2010: Cerenis And Novasep Receive EUR10.7 Million Funding From French Government For Development Of CER-001 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59

List of Tables

Number of Products under Development for Arteriosclerosis, H2 2014 8
Number of Products under Development for Arteriosclerosis - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
Arteriosclerosis - Pipeline by Johnson and Johnson, H2 2014 17
Arteriosclerosis - Pipeline by Kowa Company, Ltd., H2 2014 18
Arteriosclerosis - Pipeline by Nippon Shinyaku Co., Ltd., H2 2014 19
Arteriosclerosis - Pipeline by KunWha Pharmaceutical Co., Ltd., H2 2014 20
Arteriosclerosis - Pipeline by AnGes MG, Inc., H2 2014 21
Arteriosclerosis - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2014 22
Arteriosclerosis - Pipeline by CytoTools AG, H2 2014 23
Assessment by Monotherapy Products, H2 2014 24
Number of Products by Stage and Target, H2 2014 26
Number of Products by Stage and Mechanism of Action, H2 2014 28
Number of Products by Stage and Route of Administration, H2 2014 30
Number of Products by Stage and Molecule Type, H2 2014 32
Arteriosclerosis Therapeutics - Recent Pipeline Updates, H2 2014 46
Arteriosclerosis - Dormant Projects, H2 2014 50
Arteriosclerosis - Discontinued Products, H2 2014 51

List of Figures

Number of Products under Development for Arteriosclerosis, H2 2014 8
Number of Products under Development for Arteriosclerosis - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Products, H2 2014 14
Assessment by Monotherapy Products, H2 2014 24
Number of Products by Top 10 Target, H2 2014 25
Number of Products by Stage and Top 10 Target, H2 2014 26
Number of Products by Top 10 Mechanism of Action, H2 2014 27
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 28
Number of Products by Top 10 Route of Administration, H2 2014 29
Number of Products by Stage and Top 10 Route of Administration, H2 2014 30
Number of Products by Top 10 Molecule Type, H2 2014 31
Number of Products by Stage and Top 10 Molecule Type, H2 2014 32

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

  • $ 4995
  • Industry report
  • October 2016
  • by GBI Research

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth Summary Cardiovascular disease (CVD) covers a range of difference ...

Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023

Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023

Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Peripheral Arterial ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.